Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Power Of Proprietary Drug Names To Be Studied By US FDA

Executive Summary

FDA is worried about drug names that could appear to overstate efficacy and impact consumer and healthcare provider perceptions of the product.

You may also be interested in...



Celebrity Takes Role In US FDA Study Of Rx Drug Endorsements

Agency hasn't named the celebrity that will participate in the study on the impact that celebrity and non-celebrity endorsements have on consumer perceptions about Rx drugs.

Epidiolex Almost Didn't Get Proprietary Name Because Of Confusion With OTC Pedia-Lax

US FDA's lead name reviewer laid out slew of reasons why the two names could be confused; her bosses agreed with the individual points, but felt that mitigation measures to avoid confusion were sufficient when considered holistically. 

PhRMA Criticizes 'Exponential Pace' Of FDA Rx Drug Advertising Studies

US FDA responds to comments on proposed study of product disclosures and study of amount and location of risk information.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141517

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel